3 Export Formulation, Zinc Oxide and Footwear Stocks With a Strong Future Roadmap: Lincoln Pharmaceuticals, JG Chemicals and Redtape

Export formulation, zinc oxide and footwear stocks give investors exposure to medicines, industrial chemicals and footwear used every day. Volumes, store additions and margins decide how much of that demand turns into profit.

This list covers three export formulation, zinc oxide and footwear stocks: Lincoln Pharmaceuticals for formulations sold in India and emerging export markets, JG Chemicals for zinc oxide used in tyres, ceramics, paints and other industrial products and Redtape for footwear, apparel and accessories sold through its own brand stores and online channels. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Export Formulation, Zinc Oxide and Footwear Stocks?

Export formulation, zinc oxide and footwear stocks are shares of companies that make health products, chemicals or run restaurants. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.

Export Formulation, Zinc Oxide and Footwear Stocks at a Glance

The table compares size, valuation, return on equity and debt for the three export formulation, zinc oxide and footwear stocks as of the 14 Oct 2026 close.

Among healthcare, chemicals and consumer stocks, all three trade at a discount to their industry P/E multiples.

Why Do Export Formulation, Zinc Oxide and Footwear Stocks Have a Strong Roadmap in India?

Export formulation, zinc oxide and footwear stocks have a strong roadmap in India because export demand for medicines, tyre and paint output and rising spending on footwear keep adding volumes for these firms. Three drivers stand out.

• Pharma exports: Emerging markets add demand for formulations.
• Industrial demand: Tyres, ceramics and paints use zinc oxide.
• Brand spending: Shoppers choose branded footwear and apparel.

Lincoln Pharmaceuticals: Formulations for India and Export Markets Build the Next Leg

Lincoln Pharma's roadmap rests on formulations sold in India and emerging export markets, with a broad product list supporting revenue.

Revenue grew from Rs 482.12 crore in FY22 to Rs 704.48 crore in FY26, a 46.1% rise, and FY26 revenue was 9.1% higher than FY25. FY26 net profit rose 6.7% to Rs 87.89 crore. Over four years, net profit rose from Rs 69.36 crore in FY22 to Rs 87.89 crore. In Q1 FY27, revenue grew 19.0% to Rs 201.54 crore, and net profit rose 30.9% to Rs 36.23 crore.

Debt to equity is 0.01 and return on equity is 11.60%. The dividend yield is 0.32%. At a P/E of 11.64 against an industry P/E of 37.59, the stock trades below its industry multiple.

What to watch: The P/E of 11.64 against an industry P/E of 37.59 leaves valuation less stretched, so the next quarters' growth is the figure to follow.

JG Chemicals: Zinc Oxide Demand Builds the Next Leg

JG Chemicals' roadmap rests on zinc oxide used in tyres, ceramics, paints and other industrial products, with steady industrial demand supporting volumes.

Revenue grew from Rs 623.05 crore in FY22 to Rs 988.77 crore in FY26, a 58.7% rise, and FY26 revenue was 15.2% higher than FY25. FY26 net profit rose 2.8% to Rs 68.65 crore. Over four years, net profit rose from Rs 43.13 crore in FY22 to Rs 68.65 crore. In Q1 FY27, revenue grew 43.8% to Rs 318.38 crore, and net profit rose 59.7% to Rs 26.12 crore. Operating margin was 10.09% in FY26 and 11.48% in Q1 FY27 against 10.65% a year earlier.

Debt to equity is 0.01 and return on equity is 12.47%. FY26 operating cash flow was Rs 43.57 crore against capital expenditure of Rs 39.03 crore. The dividend yield is 0.16%. At a P/E of 31.94 against an industry P/E of 36.60, the stock trades below its industry multiple.

What to watch: Q1 FY27 operating margin was 11.48% against 10.09% for FY26, so margin stability is the figure to follow as volumes grow.

Redtape: A Footwear Brand Anchors the Roadmap

Redtape's roadmap rests on footwear, apparel and accessories sold through its own brand stores and online channels, with store expansion supporting growth.

FY26 revenue was Rs 2,551.61 crore, 17.5% higher than FY25. FY26 net profit rose 41.5% to Rs 240.55 crore. In Q1 FY27, revenue grew 4.8% to Rs 496.42 crore, and net profit rose 15.2% to Rs 44.48 crore. Operating margin was 20.07% in FY26 and 20.50% in Q1 FY27 against 18.56% a year earlier.

Debt to equity is 0.70 and return on equity is 23.55%. FY26 operating cash flow was Rs 174.01 crore against capital expenditure of Rs 85.92 crore. Redtape paid a dividend of Rs 2 per share for FY26, a yield of 1.76%. At a P/E of 25.49 against an industry P/E of 66.59, the stock trades below its industry multiple.

What to watch: Q1 FY27 operating margin was 20.50% against 20.07% for FY26, so margin stability is the figure to follow as volumes grow.

Best Export Formulation, Zinc Oxide and Footwear Stocks in India: Lincoln Pharma vs JG Chemicals vs Redtape on Key Financials

Among the best export formulation, zinc oxide and footwear stocks in India, Lincoln Pharma leads on the lowest P/E and the lowest debt to equity; JG Chemicals leads on Q1 FY27 revenue growth and Q1 FY27 net profit growth; Redtape leads on FY26 revenue growth and FY26 net profit growth. The table puts the numbers side by side.

Healthcare, chemicals and food earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.

How to Evaluate Export Formulation, Zinc Oxide and Footwear Stocks to Buy Before You Invest

A short checklist keeps the research consistent when you screen export formulation, zinc oxide and footwear stocks and shortlist export formulation, zinc oxide and footwear stocks to buy.

1. Compare each stock's P/E with its industry P/E, which differs by company here.
2. Check revenue growth, operating margin and cash flow together.
3. Check whether revenue growth is turning into profit growth, not only sales.
4. Read operating cash flow against capital expenditure to see how growth is funded.
5. Watch debt to equity and interest cover before sizing a position.
6. Spread exposure across companies and business lines instead of one demand cycle.

Check the Univest Screener for live data on these export formulation, zinc oxide and footwear stocks

Risks to Consider Before Investing in Export Formulation, Zinc Oxide and Footwear Stocks

• Consumer demand: Spending patterns can shift sales between quarters.
• Input costs: Changes in raw material prices can affect margins.
• Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.

Download the Univest iOS App or Univest Android App to track Lincoln Pharma, JG Chemicals and Redtape live.

Annual reports and quarterly result presentations are the most reliable places to verify the numbers quoted here, because they show segment details, management commentary and the notes behind each figure.

Final Take: Which Stock Has the Strongest Roadmap?

These three healthcare, chemicals and consumer stocks cover formulations, zinc oxide and footwear. Lincoln Pharma leads on the lowest P/E and the lowest debt to equity; JG Chemicals leads on Q1 FY27 revenue growth and Q1 FY27 net profit growth; Redtape leads on FY26 revenue growth and FY26 net profit growth.

Across export formulation, zinc oxide and footwear stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the export formulation, zinc oxide and footwear stocks to buy discussed here.

FAQs on Export Formulation, Zinc Oxide and Footwear Stocks

Which are the best export formulation, zinc oxide and footwear stocks in India with a strong roadmap?

Ans. Lincoln Pharmaceuticals, JG Chemicals and Redtape stand out for their roadmaps in formulations, zinc oxide and footwear. FY26 revenue growth was 9.1% at Lincoln Pharma, 15.2% at JG Chemicals and 17.5% at Redtape, and return on equity ranges from 11.60% to 23.55%.

Is Lincoln Pharmaceuticals a good stock to buy now?

Ans. Lincoln Pharmaceuticals has a debt to equity ratio of 0.01, a return on equity of 11.60% and a P/E of 11.64 against an industry P/E of 37.59. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.

What is the P/E ratio of Lincoln Pharma, JG Chemicals and Redtape?

Ans. The P/E ratio is 11.64 for Lincoln Pharma (industry 37.59), 31.94 for JG Chemicals (industry 36.60) and 25.49 for Redtape (industry 66.59). All of them trade below the industry multiple.

Which of these export formulation, zinc oxide and footwear stocks has the highest return on equity?

Ans. Redtape has the highest return on equity at 23.55%, followed by JG Chemicals at 12.47% and Lincoln Pharmaceuticals at 11.60%.

What are the risks of investing in export formulation, zinc oxide and footwear stocks?

Ans. The main risks are consumer demand, input costs and quarterly trends. Spending patterns can shift sales between quarters.

How did Lincoln Pharma, JG Chemicals and Redtape perform in Q1 FY27?

Ans. Lincoln Pharmaceuticals reported revenue of Rs 201.54 crore, up 19.0% year on year, and net profit rose 30.9% to Rs 36.23 crore. JG Chemicals reported revenue of Rs 318.38 crore, up 43.8% year on year, and net profit rose 59.7% to Rs 26.12 crore. Redtape reported revenue of Rs 496.42 crore, up 4.8% year on year, and net profit rose 15.2% to Rs 44.48 crore.

Do export formulation, zinc oxide and footwear stocks pay dividends?

Ans. Yes, all three companies pay dividends. The dividend yield is 0.32% for Lincoln Pharma, 0.16% for JG Chemicals and 1.76% for Redtape, based on dividends declared for FY26.

How can I invest in export formulation, zinc oxide and footwear stocks in India?

Ans. You can buy export formulation, zinc oxide and footwear stocks through a demat and trading account on NSE or BSE after checking each company's financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.